問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Hematology & Oncology

Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Hematology & Oncology

更新時間：2023-09-19

謝燿宇Hsieh, Yao-Yu
  • Principal Investigator
  • Clinical Trial Experience (year) 13 years 3 個月

Recruiting Trial

52Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

謝燿宇

List

92Cases

2020-10-20 - 2022-04-28

Phase III

A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

  • Condition/Disease

    Primary Immune Thrombocytopenia(ITP)

  • Test Drug

    Rozanolixizumab

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2019-09-01 - 2022-08-31

Phase I

A PHASE 1 DOSE FINDING/EXPANSION STUDY OF HLX55, A MONOCLONAL ANTIBODY TARGETING TYROSINEPROTEIN KINASE MET (C-MET) IN PATIENTS WITH ADVANCED SOLID TUMORS REFRACTORY TO STANDARD THERAPY

  • Condition/Disease

    solid tumor

  • Test Drug

    HLX55

Participate Sites
4Sites

Recruiting4Sites

2017-06-08 - 2019-04-30

Phase II

An Open-Label, Phase II Study to Evaluate the Efficacy and Safety of SCB01A in Subjects with Recurrent or Metastatic Squamous Cell Head and Neck Cancer Who Have Failed Platinum-Based Treatment

  • Condition/Disease

    Squamous Cell Head and Neck Cancer

  • Test Drug

    SCB01A

Participate Sites
4Sites

Terminated4Sites

張牧新
Taipei Veterans General Hospital

Division of Hematology & Oncology

夏和雄
Taipei Medical University Hospital

Division of Hematology & Oncology

2015-01-15 - 2023-06-06

Phase III

A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer.

  • Condition/Disease

    hormone receptor positive, HER2-negative, advanced breast cancer.

  • Test Drug

    LEE011

Participate Sites
8Sites

Terminated8Sites

2016-01-01 - 2019-12-31

Phase I

A multi-center, randomized open label study to assess the systemic exposure, efficacy, and safety of 450 mg ceritinib taken with a low-fat meal and 600 mg ceritinib taken with a low-fat meal as compared with that of 750 mg ceritinib taken in the fasted state in adult patients with ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC)

  • Condition/Disease

    ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC)

  • Test Drug

    LDK378

Participate Sites
6Sites

Terminated5Sites

夏德椿
China Medical University Hospital-Taipei

未分科

2014-02-01 - 2016-05-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2014-03-31 - 2022-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2021-08-01 - 2023-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2018-08-18 - 2022-07-11

Phase III

FIGHT: A Phase 3 Randomized, Double-Blind, Controlled Study Evaluating FPA144 and Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase 3 Preceded by Dose-Finding in Phase 1

  • Condition/Disease

    Untreated Advanced Gastric and Gastroesophageal Cancer

  • Test Drug

    FPA144

Participate Sites
9Sites

Not yet recruiting3Sites

Recruiting1Sites

Terminated4Sites

白禮源
China Medical University Hospital-Taipei

未分科

2017-05-09 - 2018-04-22

Phase I/II

A Phase 1/2, Open-label Randomized Study of Ulocuplumab (BMS-936564) in Combination With Low Dose Cytarabine in Subjects With Newly Diagnosed Acute Myeloid Leukemia

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    Ulocuplumab (BMS-936564)

Participate Sites
6Sites

Terminated5Sites

1 6 7 8 9 10
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB